SCHEMBL2882802

SCHEMBL2882802

O=C1NC(=O)C(=Cc2ccc3ncccc3c2)S1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 4/20 0.79
PIK3CD O00329 3/20 0.79
CSNK2A2 P19784 3/20 0.79
PIK3CA P42336 3/20 0.79
PIK3CG P48736 3/20 0.79
CLK1 P49759 3/20 0.79
DYRK1A Q13627 3/20 0.79
CSNK2B P67870 2/20 0.79
CSNK2A1 P68400 2/20 0.79
DYRK2 Q92630 2/20 0.79
DYRK1B Q9Y463 2/20 0.79
CLK3 P49761 1/20 0.79
HASPIN Q8TF76 1/20 0.79
MYLK2 Q9H1R3 1/20 0.79
CLK4 Q9HAZ1 1/20 0.79
STK17A Q9UEE5 1/20 0.79
CISD1 Q9NZ45 5/20 0.71
PIK3CB P42338 2/20 0.71
MTOR P42345 2/20 0.71
MAOB P27338 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2882800 1.00 PIM1 (0.79) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
Trifluoroacetic Acid SCHEMBL2423270 0.90 PIM1 (0.65) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
Trifluoroacetic Acid SCHEMBL2423268 0.90 PIM1 (0.65) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
SCHEMBL497535 0.88 PIM1 (1.00) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
SCHEMBL497023 0.88 CLK1 (0.74) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
SCHEMBL497536 0.88 PIM1 (1.00) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
SCHEMBL497022 0.88 CLK1 (0.74) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
SCHEMBL1249852 0.84 GSK3B (0.60) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
SCHEMBL1249857 0.84 GSK3B (0.60) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG
SCHEMBL668617 0.83 CISD1 (1.00) PIM1PIK3CDCSNK2A2PIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 US claimed
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 US claimed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 US claimed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 US claimed
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 US disclosed
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-12-10 US disclosed
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2008-12-11 US disclosed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 US disclosed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 US disclosed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 EP disclosed
EP-1531813-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY Applied Research Systems ARS Holding N.V. (AN) 2005-05-25 EP disclosed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 WO disclosed
WO-2004006916-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES ZAP70, BRCA1, ZYX PIM1 2247/4885PIK3CD 769/4885CSNK2A2 4143/4885
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia PDPK1, PRKD3, PRKD1 PIM1 201/4885PIK3CD 39/4885CSNK2A2 388/4885
US-20050222225-A1 Use of compounds for increasing spermatozoa motility CATSPER1, PI4KB, MAN2B2 PIM1 2811/4885PIK3CD 118/4885CSNK2A2 338/4885
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis PDPK1, PIK3R4, MAP3K3 PIM1 864/4885PIK3CD 43/4885CSNK2A2 583/4885
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives BRCA1, ZAP70, F13B PIM1 2412/4885PIK3CD 771/4885CSNK2A2 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.